Capricor Therapeutics Signs Binding Term Sheet with Nippon …
WEB4 days ago · -Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a ...
Capricor Therapeutics Signs Binding Term Sheet with Nippon …
WEB5 days ago · More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the ...
Capricor Therapeutics Poised for Growth with Expanded …
WEB4 days ago · Capricor’s strengthened financial runway, now extended into 2026, allows for thorough preparation for commercial launch, manufacturing scale-up, and continued product development in Europe.
Capricor Therapeutics Shares Rise After Deramiocel Deal With …
WEB4 days ago · Published: Sept. 17, 2024, 9:51 a.m. ET. Share. Resize. By Chris Wack. Capricor Therapeutics shares were up 9% to $4.80 after the company entered into a binding term sheet with Nippon Shinyaku for ...
Capricor sells Europe rights to late-stage DMD therapy for $35M
WEB4 days ago · Now, the Kyoto-based company has agreed to a $20 million upfront payment for the rights across Europe, as well as buying around $15 million of Capricor’s stock at a 20% premium to the stock’s ...
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
WEBJul 1, 2024 · Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway.
News & Events :: Capricor Therapeutics, Inc. (CAPR)
WEBAug 7, 2024 · Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update.
Capricor Therapeutics, Inc. (CAPR)
WEBAug 7, 2024 · Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond. We are patient-focused first, while advancing precision medicine.
Capricor Therapeutics Announces Positive 3-Year Efficacy Results …
WEBSAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
EXCLUSIVE: Capricor Therapeutics Inks European Expansion ...
WEB4 days ago · Capricor will also receive an upfront payment of $20 million, additional development and sales-based milestone payments of up to $715 million, and a double-digit share of product revenue.